000145477 001__ 145477
000145477 005__ 20241030091919.0
000145477 0247_ $$2doi$$a10.1098/rsob.240015
000145477 0248_ $$2sideral$$a140328
000145477 037__ $$aART-2024-140328
000145477 041__ $$aeng
000145477 100__ $$0(orcid)0000-0001-9802-8199$$aLópez-Royo, Tresa$$uUniversidad de Zaragoza
000145477 245__ $$aDifferentially expressed lncRNAs in SOD1G93A mice skeletal muscle: H19, Myhas and Neat1 as potential biomarkers in amyotrophic later
000145477 260__ $$c2024
000145477 5060_ $$aAccess copy available to the general public$$fUnrestricted
000145477 5203_ $$aAmyotrophic lateral sclerosis (ALS) is a devastating neuromuscular disease characterized by progressive motor function and muscle mass loss. Despite extensive research in the field, the underlying causes of ALS remain incompletely understood, contributing to the absence of specific diagnostic and prognostic biomarkers and effective therapies. This study investigates the expression of long-non-coding RNAs (lncRNAs) in skeletal muscle as a potential source of biomarkers and therapeutic targets for the disease. The expression profiles of 12 lncRNAs, selected from the literature, were evaluated across different disease stages in tissue and muscle biopsies from the SOD1G93A transgenic mouse model of ALS. Nine out of the 12 lncRNAs were differentially expressed, with Pvt1, H19 and Neat1 showing notable increases in the symptomatic stages of the disease, and suggesting their potential as candidate biomarkers to support diagnosis and key players in muscle pathophysiology in ALS. Furthermore, the progression of Myhas and H19 RNA levels across disease stages correlated with longevity in the SOD1G93A animal model, effectively discriminating between long- and short-term survival individuals, thereby highlighting their potential as prognostic indicators. These findings underscore the involvement of lncRNAs, especially H19 and Myhas, in ALS pathophysiology, offering novel insights for diagnostic, prognostic and therapeutic targets.
000145477 536__ $$9info:eu-repo/grantAgreement/ES/DGA/A19-23R$$9info:eu-repo/grantAgreement/ES/FIS/PI21-00286$$9info:eu-repo/grantAgreement/ES/ISCIII/CB18-05-0037$$9info:eu-repo/grantAgreement/ES/ISCIII/FEDER/PI21-00372$$9info:eu-repo/grantAgreement/ES/MCIU/FPU19-05625$$9info:eu-repo/grantAgreement/ES/MICINN-AEI/PRTR-C17.I1
000145477 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000145477 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000145477 700__ $$0(orcid)0000-0002-7277-4318$$aMoreno-Martínez, Laura$$uUniversidad de Zaragoza
000145477 700__ $$0(orcid)0000-0001-5740-0185$$aZaragoza, Pilar$$uUniversidad de Zaragoza
000145477 700__ $$0(orcid)0000-0001-7646-386X$$aGarcía-Redondo, Alberto
000145477 700__ $$0(orcid)0000-0002-7477-8742$$aManzano, Raquel$$uUniversidad de Zaragoza
000145477 700__ $$0(orcid)0000-0001-5687-6704$$aOsta, Rosario$$uUniversidad de Zaragoza
000145477 7102_ $$11001$$2420$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Genética
000145477 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000145477 773__ $$g14, 10 (2024), 10 pp.$$pOpen biol.$$tOpen biology$$x2046-2441
000145477 8564_ $$s1236225$$uhttps://zaguan.unizar.es/record/145477/files/texto_completo.pdf$$yVersión publicada
000145477 8564_ $$s2799228$$uhttps://zaguan.unizar.es/record/145477/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000145477 909CO $$ooai:zaguan.unizar.es:145477$$particulos$$pdriver
000145477 951__ $$a2024-10-30-08:49:14
000145477 980__ $$aARTICLE